Neither did the phase II trials (114, 125) nor the phase III READY trial (117) successfully retrieve data confirming that Src is sufficiently inhibited by dasatinib inside the prostate tumours as discussed by the investigators. This evidence concerns the gene SRC and prostate neoplasm.